candesartan has been researched along with Prosthesis Durability in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benedetto, U | 1 |
| Melina, G | 1 |
| Refice, S | 1 |
| di Bartolomeo, R | 1 |
| Roscitano, A | 1 |
| Angeloni, E | 1 |
| Sinatra, R | 1 |
1 trial available for candesartan and Prosthesis Durability
| Article | Year |
|---|---|
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-C | 2010 |